Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Luqa Pharma In-Licenses Scar Treatment from Stratpharma

publication date: Aug 2, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Luqa Pharmaceuticals, a Hong Kong company that specializes in dermatology products, has in-licensed exclusive China rights to Strataderm®, a scar treatment, from Stratpharma AG of Switzerland. Strataderm has already been approved by the SFDA; Luqa plans to begin marketing the drug to hospital and retail accounts in Q4 of 2012. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors